THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH) Files An 8-K Regulation FD Disclosure

THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

The information in this Current Report (including Exhibit99.1) is being furnished and shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit99.1) shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

On February7, 2018, Theravance Biopharma,Inc. (the “Company”) issued a press release announcing a global collaboration with Janssen Biotech,Inc. (one of the Janssen Pharmaceutical Companies of Johnson& Johnson) for TD-1473 and related back-up compounds for inflammatory intestinal diseases. Members of the Company’s management will discuss the announcement on a conference call today at 8:00a.m.Eastern Time. A copy of the press release and the slide presentation to be presented during the conference call are furnished as Exhibits 99.1 and 99.2 to this report and are incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

99.1

Press Release Dated February7, 2018

99.2

Theravance Biopharma and Janssen Biotech,Inc. Global Collaboration for TD-1473 Slide Presentation Dated February7, 2018


Theravance Biopharma, Inc. Exhibit
EX-99.1 2 a18-5540_1ex99d1.htm EX-99.1 Exhibit 99.1     Theravance Biopharma Enters Global Collaboration with Janssen for TD-1473 in Inflammatory Intestinal Diseases   Theravance Biopharma Together with Janssen will Jointly Develop and Commercialize TD-1473,…
To view the full exhibit click here

About THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH)

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

An ad to help with our costs